Last reviewed · How we verify

Hyperpolarized Xe129

Mario Castro, MD, MPH · Phase 2 active Small molecule

Hyperpolarized Xe129 is a Small molecule drug developed by Mario Castro, MD, MPH. It is currently in Phase 2 development for Diagnosis and monitoring of cancer. Also known as: HP Xenon, 129Xe, Xenon MRI, 129 HXe MRI.

Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions.

Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions. Used for Diagnosis and monitoring of cancer.

Likelihood of approval
13.3% vs 15.3% industry baseline
If approved by FDA: likely 2031–2034
Steps remaining: Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 2 → approval rate +15.3pp
    Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
  • Oncology Phase 2 attrition -2.0pp
    Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2031–2034
EMA EU 2032–2035 +0.7 yr
MHRA GB 2032–2035 +0.7 yr
Health Canada CA 2032–2036 +0.9 yr
TGA AU 2032–2036 +1.2 yr
PMDA JP 2032–2036 +1.5 yr
NMPA CN 2033–2037 +2.3 yr
MFDS KR 2032–2036 +1.4 yr
CDSCO IN 2032–2037 +1.8 yr
ANVISA BR 2033–2037 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameHyperpolarized Xe129
Also known asHP Xenon, 129Xe, Xenon MRI, 129 HXe MRI, Xenon, 129Xe, HP Xenon
SponsorMario Castro, MD, MPH
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 2

Mechanism of action

It works by exploiting the difference in magnetic properties between hyperpolarized xenon-129 and regular xenon-129, allowing for more detailed imaging of tissues and tumors. This can help doctors diagnose and monitor cancer more accurately.

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Hyperpolarized Xe129

What is Hyperpolarized Xe129?

Hyperpolarized Xe129 is a Small molecule drug developed by Mario Castro, MD, MPH, indicated for Diagnosis and monitoring of cancer.

How does Hyperpolarized Xe129 work?

Hyperpolarized Xe129 is a magnetic resonance imaging (MRI) contrast agent that enhances the visibility of tumors and other lesions.

What is Hyperpolarized Xe129 used for?

Hyperpolarized Xe129 is indicated for Diagnosis and monitoring of cancer.

Who makes Hyperpolarized Xe129?

Hyperpolarized Xe129 is developed by Mario Castro, MD, MPH (see full Mario Castro, MD, MPH pipeline at /company/mario-castro-md-mph).

Is Hyperpolarized Xe129 also known as anything else?

Hyperpolarized Xe129 is also known as HP Xenon, 129Xe, Xenon MRI, 129 HXe MRI, Xenon, 129Xe, HP Xenon.

What development phase is Hyperpolarized Xe129 in?

Hyperpolarized Xe129 is in Phase 2.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing